Learn about how the new Ion Torrent Genexus System is addressing key challenges to next-generation sequencing (NGS) implementation, like hands-on time, time-to-result, user expertise, and ...
Next-generation sequencing (NGS) has become increasingly popular with testing labs, as it allows them to obtain more data in less time and with minimal input. In this webinar, we will explore the Ion ...
Faster genomics-based diagnosis may accelerate targeted treatment of patients with myeloid neoplasms
Identifying recurrent genetic alterations in myeloid neoplasms has improved diagnosis and expanded targeted treatments available to patients. However, treatment initiation can be delayed by the ...
Ion Torrent Oncomine Myeloid MRD Assays (RUO) are the first NGS-based tests to offer simultaneous DNA and RNA analysis for myeloid MRD assessment CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher ...
Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer generates results in as little as 24 hours to support timely therapy decisions A patient’s tumor profile has the potential ...
Thermo Fisher Scientific Inc. TMO recently announced a partnership with the National Cancer Institute (“NCI”) for the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results